Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2005 / Cilt: 15 - Sayı: 3

The prognostic significance of pretreatment serum LDH level in non-small cell lung cancer

Küçük hücreli dışı akciğer kanserli hastalarda tedavi öncesi serum LDH düzeylerinin prognostik önemi

Pages
115–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

More comprehensive studies are needed in this area.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The aim of this study was to investigate the effect of pretreatment LDH levels on the prognosis of patients with nonsmall-cell lung cancer.
📊
Key Findings & Data:Normal LDH level group had significantly better prognosis (12.9 months) compared to high LDH level group (6.5 months) (p=0.0011).
💡
Conclusion & Impact:More comprehensive studies are needed in this area.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Sağkalım · Karsinom · küçük hücreli dışı akciğer

Abstract

The aim of this study was to investigate the effect of pretreatment LDH levels on the prognosis of patients with nonsmall-cell lung cancer. Ninety-six patients who were diagnosed with non-small-cell lung cancer in the departments of medical oncology and chest disease of Karadeniz Technical University and the department of medical oncology of Ankara University and had LDH measurements were included in the study. Normal LDH level group had significantly better prognosis (12.9 months) compared to high LDH level group (6.5 months) (p=0.0011). In the subgroup analysis of LDH groups, the groups were statistically uniform in age, sex, performance status, stage and preferred treatment modality (surgery, radiotherapy, chemotherapy) parameters. The poor prognosis, seen in high LDH level group may be due to their resistance to chemotherapy and high recurrence and low remission rates. More comprehensive studies are needed in this area.

Özet

Bu çalışmada küçük hücreli akciğer kanseri (KHDAK) tanısı almış olguların tanı sırasındaki LDH düzeylerinin bu hastaların prognozları üzerine etkilerininin araştırılması planlandı. Çalışmaya KTÜ Tıp Fakültesi tıbbi onkoloji ve göğüs hastalıkları kliniğine ve Ankara Üniversitesi Tıp Fakültesi tıbbi onkoloji kliniğine başvuran tanıdaki LDH seviyeleri bilinen küçük hücreli dışı akciğer kanseri tanısı almış 96 hasta dahil edildi. Yüksek LDH seviyeli gruptaki hastaların sağkalım süreleri (6.5 ay) normal LDH seviyeli gruba (12.9 ay) göre anlamlı oranda daha kısa bulundu (p=0.0011). Serum LDH seviyelerine göre normal ve yüksek olan gruplardaki hastaların alt grup analizlerinde, hastalar arasında yaş, cinsiyet, performans durumu, evre durumu, cerrahi, kemoterapi ve radyoterapi uygulanıp uygulanmadığı açısından fark yoktu. Yüksek LDH seviyeli hastaların kötü prognozlu olmalarının sebebi bu hastaların kemoterapiye daha dirençli, rekürrens oranlarının yüksek ve düşük remisyon oranlarına sahip olmaları olabilir. Bu konuda daha kapsamlı çalışmalara gerek duyulmaktadır.

🔖

Cite This Article

ÖZDEMİR, F., BEKTAŞ, Ö., URUÇ, İ., BÜLBÜL, Y., TOPBAŞ, M., KAVGACI, H., YILMAZ, M., AYDIN, F. (2005). The prognostic significance of pretreatment serum LDH level in non-small cell lung cancer. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 15 - Sayı: 3, 115–119. https://ajindex.com/articles/323119

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. McKenna RJ, Movsas B, Shin DM, et al. Nonsmall- cell lung cancer, mesothelioma, and thymoma. In: Cancer Management: A Multidisciplinary Approach. Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds). 6th ed. Melville, PRR, 2002: 111-148. 2. Kodaira T, Yamakawa K, Taniguchi H, et al. Clinical efficacy of concurrent carboplatin, etoposide, and definitive radiotherapy for stage 3 non-small-cell lung cancer: consideration as to therapeutic outcomes and morbidity. Nippon Igaku Hoshasen Gakkai Zasshi 58: 497-502, 1998. 3. Muraki M, Toda Y, Haraguchi R, et al. Study of prognostic factors of survival in patientswith unresectable non-small cell lung cancer. Gan To Kagaku Ryoho 18: 585-92, 1991. 4. Sorensen. Chemotherapy for advenced adenocarcinoma of the lung: the Copenhagen study and review of the literature. Semin Oncol 15(6Suppl7): 56-7, 1988. 5. Gregorc V, Darwish S, Ludovini V, et al. The clinical relevance of Bcl-2, Rb and p53 expression in advenced non-small cell lung cancer. Lung Cancer 42: 275-81, 2003. 6. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161: 589-94, 2000. 7. Hirasawa Y, Takada M, Komiya T, et al. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer. Anticancer Res 18: 4713-6, 1998. 8. Nieder C, Nestle U, Ukena D, et al. Tumor markers as prognostic factors in non-small cell bronchial carcinoma. Strahlenther Onkol 171: 587-93, 1995. 9. Morra E. The biological markers of non- Hodgkin's lymphomas: their role in diagnosis, prognostic assessment and therapeutic strategy. Int J Biol Markers 14: 149-53, 1999. 10. O'Connell JP, Kris MG, Gralla RJ, et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4: 1604-14, 1986. 11. Stokkel MP, Van Eck-Smit BL, Zwinderman AH, et al. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma. Int J Biol Markers 12: 162-7, 1997.